单独使用里瓦罗克萨班纳米颗粒和与西塔格利普丁组合对糖尿病老鼠模型的免疫调节效应
Mohamed M Elbadr1, Heba A Galal2, Helal F Hetta3
1Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Diseases (Basel, Switzerland)
|March 26, 2025
概括
在糖尿病大鼠中,纳米-里瓦罗克萨班 (NRX) 与西塔格利普丁 (SITA) 结合有效降低了炎症并恢复了免疫平衡. 这种组合疗法显示出通过调节免疫反应来管理糖尿病并发症的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
- 纳米医学是一种纳米医学.
背景情况:
- 慢性炎症和免疫失调是糖尿病并发症的核心原因.
- 里瓦罗克萨班 (RX) 和西塔格利普丁 (SITA) 分别是血栓栓塞和血糖控制的已知治疗方法.
- 这项研究研究了纳米-里瓦罗克萨班 (NRX) 和其与SITA的组合,用于糖尿病免疫调节.
研究的目的:
- 评估单独使用NRX和与SITA结合使用的治疗潜力.
- 评估对链毒素 (STZ) 诱导的糖尿病大鼠的炎症和免疫平衡的影响.
- 探索一种用于管理糖尿病并发症的新策略.
主要方法:
- 在使用STZ (60 mg/kg) 的老鼠中诱导的2型糖尿病.
- 治疗组:对照组,STZ糖尿病患者,RX,NRX和NRX+SITA.
- 分析包括血糖,凝血标志物,细胞因子 (亲和抗炎) 概况和免疫器官的组织病理学. 通过免疫组织化学评估肝脏NF-κB表达.
主要成果:
- 由STZ诱导的糖尿病增加了促炎和抗炎细胞因子,增加了NF-κB表达,并导致器官组织病理学.
- NRX治疗显著降低了炎症,改善了器官组织病理学,并降低了NF-κB表达.
- 组合疗法 (NRX + SITA) 显示出优越的免疫调节,增强的细胞因子恢复,减少NF-κB,以及几乎完全的组织病理正常化.
结论:
- 结合基于纳米粒子的药物输送 (NRX) 与西塔利普丁提供了一个有前途的治疗策略.
- 这种方法实现了优越的免疫调节和炎症控制,用于管理糖尿病并发症.
- 这些发现突显了NRX+SITA在改善糖尿病管理方面的潜力.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
146
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
146
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
01:24Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
01:06Oral Hypoglycemic Agents: Glinides
116
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
116